Involvement of κ-opioid and σ receptors in short-term memory in mice

Masayuki Hiramatsu, Takashi Hoshino, Tsutomu Kameyama, Toshitaka Nabeshima

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

κ-Opioid receptor agonists, trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate (U-50,488H) and dynorphin A-(1-13), improve impairments of learning and memory in mice and rats. σ Receptor agonists, (+)-N-allylnormetazocine ((+)-SKF10,047) and 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride (SA4503), also reverse learning and memory impairment in various animal models. However, the mechanisms underlying these effects are not well understood. In the present study, the effect of coadministration of U-50,488H and (+)-SKF10,047 on scopolamine-induced memory impairment was investigated in mice using spontaneous alternation performance in a Y-maze. U-50,488H (0.21-2.15 μmol/kg, subcutaneously (s.c.)) and (+)-SKF10,047 (0.10-1.02 μmol/kg, s.c.) 25 min before the Y-maze test improved the impairment of spontaneous alternation induced by scopolamine (1.65 μmol/kg, s.c.). When U-50,488H and (+)-SKF10,047 were coadministered, no additive effect was observed. Furthermore, the ameliorating effects of U-50,488H and (+)-SKF10,047 were not antagonized by a selective σ receptor antagonist, N,N-dipropyl-2-[4-methoxy-3-(2-phenylenoxy)-phenyl]-ethylamine monohydrochloride (NE-100), and a selective κ-opioid receptor antagonist, nor-binaltorphimine, respectively. These results suggest that the mechanisms underlying the ameliorating effects on memory impairment are independent and no direct modulation exists in κ-opioid and σ receptors-mediated mechanisms.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalEuropean Journal of Pharmacology
Volume453
Issue number1
DOIs
Publication statusPublished - 18-10-2002

Fingerprint

(trans)-Isomer 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide
Opioid Receptors
Short-Term Memory
Scopolamine Hydrobromide
Learning
Narcotic Antagonists
Animal Models

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Hiramatsu, Masayuki ; Hoshino, Takashi ; Kameyama, Tsutomu ; Nabeshima, Toshitaka. / Involvement of κ-opioid and σ receptors in short-term memory in mice. In: European Journal of Pharmacology. 2002 ; Vol. 453, No. 1. pp. 91-98.
@article{505a771b89184456914bdc48c4de8da8,
title = "Involvement of κ-opioid and σ receptors in short-term memory in mice",
abstract = "κ-Opioid receptor agonists, trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate (U-50,488H) and dynorphin A-(1-13), improve impairments of learning and memory in mice and rats. σ Receptor agonists, (+)-N-allylnormetazocine ((+)-SKF10,047) and 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride (SA4503), also reverse learning and memory impairment in various animal models. However, the mechanisms underlying these effects are not well understood. In the present study, the effect of coadministration of U-50,488H and (+)-SKF10,047 on scopolamine-induced memory impairment was investigated in mice using spontaneous alternation performance in a Y-maze. U-50,488H (0.21-2.15 μmol/kg, subcutaneously (s.c.)) and (+)-SKF10,047 (0.10-1.02 μmol/kg, s.c.) 25 min before the Y-maze test improved the impairment of spontaneous alternation induced by scopolamine (1.65 μmol/kg, s.c.). When U-50,488H and (+)-SKF10,047 were coadministered, no additive effect was observed. Furthermore, the ameliorating effects of U-50,488H and (+)-SKF10,047 were not antagonized by a selective σ receptor antagonist, N,N-dipropyl-2-[4-methoxy-3-(2-phenylenoxy)-phenyl]-ethylamine monohydrochloride (NE-100), and a selective κ-opioid receptor antagonist, nor-binaltorphimine, respectively. These results suggest that the mechanisms underlying the ameliorating effects on memory impairment are independent and no direct modulation exists in κ-opioid and σ receptors-mediated mechanisms.",
author = "Masayuki Hiramatsu and Takashi Hoshino and Tsutomu Kameyama and Toshitaka Nabeshima",
year = "2002",
month = "10",
day = "18",
doi = "10.1016/S0014-2999(02)02388-9",
language = "English",
volume = "453",
pages = "91--98",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

Involvement of κ-opioid and σ receptors in short-term memory in mice. / Hiramatsu, Masayuki; Hoshino, Takashi; Kameyama, Tsutomu; Nabeshima, Toshitaka.

In: European Journal of Pharmacology, Vol. 453, No. 1, 18.10.2002, p. 91-98.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Involvement of κ-opioid and σ receptors in short-term memory in mice

AU - Hiramatsu, Masayuki

AU - Hoshino, Takashi

AU - Kameyama, Tsutomu

AU - Nabeshima, Toshitaka

PY - 2002/10/18

Y1 - 2002/10/18

N2 - κ-Opioid receptor agonists, trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate (U-50,488H) and dynorphin A-(1-13), improve impairments of learning and memory in mice and rats. σ Receptor agonists, (+)-N-allylnormetazocine ((+)-SKF10,047) and 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride (SA4503), also reverse learning and memory impairment in various animal models. However, the mechanisms underlying these effects are not well understood. In the present study, the effect of coadministration of U-50,488H and (+)-SKF10,047 on scopolamine-induced memory impairment was investigated in mice using spontaneous alternation performance in a Y-maze. U-50,488H (0.21-2.15 μmol/kg, subcutaneously (s.c.)) and (+)-SKF10,047 (0.10-1.02 μmol/kg, s.c.) 25 min before the Y-maze test improved the impairment of spontaneous alternation induced by scopolamine (1.65 μmol/kg, s.c.). When U-50,488H and (+)-SKF10,047 were coadministered, no additive effect was observed. Furthermore, the ameliorating effects of U-50,488H and (+)-SKF10,047 were not antagonized by a selective σ receptor antagonist, N,N-dipropyl-2-[4-methoxy-3-(2-phenylenoxy)-phenyl]-ethylamine monohydrochloride (NE-100), and a selective κ-opioid receptor antagonist, nor-binaltorphimine, respectively. These results suggest that the mechanisms underlying the ameliorating effects on memory impairment are independent and no direct modulation exists in κ-opioid and σ receptors-mediated mechanisms.

AB - κ-Opioid receptor agonists, trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate (U-50,488H) and dynorphin A-(1-13), improve impairments of learning and memory in mice and rats. σ Receptor agonists, (+)-N-allylnormetazocine ((+)-SKF10,047) and 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride (SA4503), also reverse learning and memory impairment in various animal models. However, the mechanisms underlying these effects are not well understood. In the present study, the effect of coadministration of U-50,488H and (+)-SKF10,047 on scopolamine-induced memory impairment was investigated in mice using spontaneous alternation performance in a Y-maze. U-50,488H (0.21-2.15 μmol/kg, subcutaneously (s.c.)) and (+)-SKF10,047 (0.10-1.02 μmol/kg, s.c.) 25 min before the Y-maze test improved the impairment of spontaneous alternation induced by scopolamine (1.65 μmol/kg, s.c.). When U-50,488H and (+)-SKF10,047 were coadministered, no additive effect was observed. Furthermore, the ameliorating effects of U-50,488H and (+)-SKF10,047 were not antagonized by a selective σ receptor antagonist, N,N-dipropyl-2-[4-methoxy-3-(2-phenylenoxy)-phenyl]-ethylamine monohydrochloride (NE-100), and a selective κ-opioid receptor antagonist, nor-binaltorphimine, respectively. These results suggest that the mechanisms underlying the ameliorating effects on memory impairment are independent and no direct modulation exists in κ-opioid and σ receptors-mediated mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0037130985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037130985&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(02)02388-9

DO - 10.1016/S0014-2999(02)02388-9

M3 - Article

C2 - 12393064

AN - SCOPUS:0037130985

VL - 453

SP - 91

EP - 98

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -